12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TH-302: Additional Phase IIb data

Additional data from the open-label, crossover, U.S. Phase IIb TH-CR-404 trial in 214 patients with previously untreated advanced pancreatic cancer showed that 240 and 340 mg/m 2 IV TH-302 plus gemcitabine non-significantly improved median OS, a secondary endpoint, vs. gemcitabine alone. Specifically, TH-302 plus gemcitabine led to a median OS of 8.7 months in the low-dose group (p=0.827) and 9.2 months in the high-dose group (p=0.8) vs. 6.9 months in the gemcitabine alone group. Threshold said the trial was not designed to detect a significant improvement in OS. The company added that patients who crossed over from...

Read the full 462 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >